The Telegraph recently spread the news that the UK PM Boris Johnson is set to kick start trade talks with the US within the next two weeks, amid frustration in Number 10 at EU “time-wasting.”
The Prime Minister will next week (March 2) publish the Government’s ‘red lines’ for its US trade negotiations which are expected to push back on US demands for its drug and health firms to have greater access to the British market.
In an apparent nod to US concerns over Britain’s tough stance on food and agricultural standards, George Eustice, the Environment Secretary, on Sunday appeared to soften the UK’s resistance to importing American chemically-treated chicken.
While the news should ideally help the GBP/USD pair, the buyers and the sellers are jostling around 1.2950 by the press time of early Monday as markets are more interested in coronavirus updates amid risk-off.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.